A possible role for STI571 in the treatment of idiopathic myelofibrosis

被引：1
|
作者：
Hasselbalch, HC [1 ]
机构：
[1] Rigshosp, Dept Hamatol L, DK-2100 Copenhagen, Denmark
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2001年 / 68卷 / 01期
关键词：
D O I：
10.1002/ajh.1153
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：63 / 64
页数：2
相关论文
共 50 条
  • [1] STI571(Gleevec) therapy in idiopathic and postpolycythemic myelofibrosis.
    Hasselbalch, HC
    Bjerrum, OW
    Jensen, BA
    Hansen, PB
    Birgens, H
    [J]. BLOOD, 2002, 100 (11) : 344B - 344B
  • [2] Another possible mechanism of resistance to STI571
    Knight, ZA
    [J]. BLOOD, 2000, 96 (12) : 4003 - 4004
  • [3] The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer
    O'Dwyer, Michael E.
    Druker, Brian J.
    [J]. CURRENT CANCER DRUG TARGETS, 2001, 1 (01) : 49 - 57
  • [4] STI571: a magic bullet?
    Verweij, J
    Judson, I
    van Oosterom, A
    [J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (15) : 1816 - 1819
  • [5] Cutaneous reactions to STI571
    Brouard, M
    Saurat, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (08): : 618 - 619
  • [6] Pharmacology of imatinib (STI571)
    Buchdunger, E
    O'Reilly, T
    Wood, J
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S28 - S36
  • [7] Cancer treatment in the STI571 era: What will change?
    Sawyers, CL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) : 13S - 16S
  • [8] STI571 as a targeted therapy for CML
    O'Dwyer, ME
    Mauro, MJ
    Druker, BJ
    [J]. CANCER INVESTIGATION, 2003, 21 (03) : 429 - 438
  • [9] STI571 in adult lymphoblastic leukemia
    Hoelzer, DH
    Goekbuget, N
    Ottmann, OG
    [J]. LEUKEMIA, 2003, 17 (03) : 660 - 660
  • [10] STI571, a molecularly targeted treatment modality for CML.
    Buchdunger, E
    Peng, B
    Ford, J
    Capdeville, R
    Resta, D
    Druker, B
    Sawyers, C
    Talpaz, M
    [J]. CLINICAL CANCER RESEARCH, 2000, 6 : 4482S - 4482S
12345